Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Medicine

Background:

• The optimal treatment strategy for pediatric Hodgkin's disease is not well-established.
• Hodgkin's disease (HD) in children requires careful consideration of treatment efficacy and long-term outcomes.

Purpose of the Study:

• To evaluate the treatment outcomes of pediatric patients (<13 years) with Hodgkin's disease.
• To compare the effectiveness of chemotherapy alone versus combined modality treatment (chemotherapy plus radiotherapy).

Main Methods:

• Retrospective review of medical records for 24 children diagnosed with Hodgkin's disease between 1980 and 1996.
• Patients were treated with chemotherapy alone (COPP, ABVD, MOPP) or combined chemotherapy and involved field radiotherapy.
• Outcomes assessed included event-free survival (EFS) and overall survival (OS) at a median follow-up of 5 years.

Main Results:

• Combined modality treatment resulted in 100% event-free survival and 100% overall survival.
• Chemotherapy alone showed lower efficacy, with 56% event-free survival and 79% overall survival.
• Four patients (27%) treated with chemotherapy alone, particularly those with Stage IIIB disease, experienced relapse.

Conclusions:

• Combined modality treatment (chemotherapy plus radiotherapy) is superior to chemotherapy alone for pediatric Hodgkin's disease.
• Six cycles of chemotherapy alone may be suboptimal for Stage IIIB Hodgkin's disease, especially with specific risk factors.
• Radiation therapy or additional chemotherapy is recommended for high-risk pediatric Hodgkin's disease patients.